Organogenesis files to sell up to $75 million in stock through at-the-market program

Organogenesis Holdings Inc. filed a prospectus supplement on August 6, 2026 for an at-the-market stock offering of up to $75,000,000 in Class A common stock. The company entered an At-The-Market Sales Agreement with BTIG, LLC and Citizens JMP Securities, LLC, dated August 6, 2026.¹

The stock trades on the Nasdaq Capital Market under the symbol ORGO, and the last reported sale price on August 5, 2026 was $2.37 per share.¹ The sales agents will be paid a commission of up to 3.0% of gross proceeds from any shares sold under the agreement.¹

The company said it intends to use net proceeds, along with existing cash and investments, for working capital and general corporate purposes, including facility expansion, manufacturing enhancements, salesforce expansion, and to fund clinical studies, regulatory approvals and additional commercial insurance coverage for its products.¹

On the product pipeline side, the company announced in April 2026 the completion of a rolling Biologics License Application submission to the FDA for ReNu, a cryopreserved amniotic suspension allograft developed for treatment of pain in symptomatic knee osteoarthritis.¹ The FDA accepted the BLA filing for ReNu in July 2026 and set a PDUFA target action date of April 24, 2027.¹

Regarding dilution, assuming 31,645,569 shares are sold at $2.37 per share for gross proceeds of $75 million, after deducting 3.0% commissions and estimated offering expenses, investors would experience immediate dilution of $0.32 per share.¹ The company's outstanding Convertible Preferred Stock carries anti-dilution price protection that adjusts its conversion price if shares are sold below the current conversion price, initially set at $3.7917 per share.¹ Assuming the full $75 million is raised at $2.37 per share, the conversion price would adjust to $3.51 per share, increasing shares issuable on conversion from 39,023,068 to 42,142,023.¹